Related Experiment Videos
Iloprost antagonizes endothelin-induced vasoconstriction in macro- and microcirculation
1Forschungslaboratorien der Schering AG, Berlin.
Eicosanoids
|January 1, 1990
Summary
Prostacyclin effectively counteracts endothelin-1 (ET-1) effects on blood pressure and blood vessels. This study shows prostacyclin acts as a functional antagonist to ET-1, impacting both systemic and local responses.
Area of Science:
- Cardiovascular Pharmacology
- Endocrinology
- Vascular Biology
Background:
- Endothelin-1 (ET-1) is a potent vasoconstrictor peptide implicated in various cardiovascular conditions.
- The role of prostacyclin in modulating ET-1's pressor effects requires further elucidation.
Purpose of the Study:
- To investigate the functional antagonism between prostacyclin and endothelin-1 in vivo.
- To determine the impact of prostacyclin on ET-1-induced systemic and local vascular responses.
Main Methods:
- Experiments were conducted in conscious Wistar rats and hamster cheek pouch models.
- Dose-dependent effects of ET-1 on blood pressure were assessed.
- The influence of indomethacin pretreatment and iloprost (a prostacyclin analogue) administration on ET-1 effects were evaluated.
Main Results:
- Endothelin-1 induced a dose-dependent, long-lasting increase in blood pressure in rats.
- Indomethacin pretreatment potentiated ET-1's pressor effect and initial hypotensive response.
- Iloprost completely reversed both the systemic pressor response and local arteriolar constriction induced by ET-1.
Conclusions:
- Prostacyclin acts as a potent functional antagonist to endothelin-1.
- These findings highlight the therapeutic potential of prostacyclin in conditions involving ET-1 mediated vasoconstriction.